205 related articles for article (PubMed ID: 30621100)
1. Small Multitarget Molecules Incorporating the Enone Moiety.
Liargkova T; Eleftheriadis N; Dekker F; Voulgari E; Avgoustakis C; Sagnou M; Mavroidi B; Pelecanou M; Hadjipavlou-Litina D
Molecules; 2019 Jan; 24(1):. PubMed ID: 30621100
[TBL] [Abstract][Full Text] [Related]
2. Simple chalcones and bis-chalcones ethers as possible pleiotropic agents.
Liargkova T; Hadjipavlou-Litina DJ; Koukoulitsa C; Voulgari E; Avgoustakis C
J Enzyme Inhib Med Chem; 2016; 31(2):302-13. PubMed ID: 25798685
[TBL] [Abstract][Full Text] [Related]
3. Ultrasound-assisted synthesis of novel chalcone, heterochalcone and bis-chalcone derivatives and the evaluation of their antioxidant properties and as acetylcholinesterase inhibitors.
Polo E; Ibarra-Arellano N; Prent-Peñaloza L; Morales-Bayuelo A; Henao J; Galdámez A; Gutiérrez M
Bioorg Chem; 2019 Sep; 90():103034. PubMed ID: 31280015
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Sang Z; Wang K; Shi J; Liu W; Tan Z
Eur J Med Chem; 2019 Sep; 178():726-739. PubMed ID: 31229875
[TBL] [Abstract][Full Text] [Related]
5. Effect on Acetylcholinesterase and Anti-oxidant Activity of Synthetic Chalcones having a Good Predicted Pharmacokinetic Profile.
Sakata RP; Figueiro M; Kawano DF; Almeida WP
Med Chem; 2017; 13(7):654-663. PubMed ID: 28545385
[TBL] [Abstract][Full Text] [Related]
6. Exploring the 2'-Hydroxy-Chalcone Framework for the Development of Dual Antioxidant and Soybean Lipoxygenase Inhibitory Agents.
Kostopoulou I; Tzani A; Polyzos NI; Karadendrou MA; Kritsi E; Pontiki E; Liargkova T; Hadjipavlou-Litina D; Zoumpoulakis P; Detsi A
Molecules; 2021 May; 26(9):. PubMed ID: 34066803
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and Evaluation of Novel Ligustrazine Derivatives as Multi-Targeted Inhibitors for the Treatment of Alzheimer's Disease.
Wu W; Liang X; Xie G; Chen L; Liu W; Luo G; Zhang P; Yu L; Zheng X; Ji H; Zhang C; Yi W
Molecules; 2018 Oct; 23(10):. PubMed ID: 30301153
[TBL] [Abstract][Full Text] [Related]
8. Bis-Amiridines as Acetylcholinesterase and Butyrylcholinesterase Inhibitors:
Makhaeva GF; Kovaleva NV; Boltneva NP; Rudakova EV; Lushchekina SV; Astakhova TY; Serkov IV; Proshin AN; Radchenko EV; Palyulin VA; Korabecny J; Soukup O; Bachurin SO; Richardson RJ
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164325
[TBL] [Abstract][Full Text] [Related]
9. Development of chalcone-O-alkylamine derivatives as multifunctional agents against Alzheimer's disease.
Bai P; Wang K; Zhang P; Shi J; Cheng X; Zhang Q; Zheng C; Cheng Y; Yang J; Lu X; Sang Z
Eur J Med Chem; 2019 Dec; 183():111737. PubMed ID: 31581002
[TBL] [Abstract][Full Text] [Related]
10. Natural and synthetic 2'-hydroxy-chalcones and aurones: synthesis, characterization and evaluation of the antioxidant and soybean lipoxygenase inhibitory activity.
Detsi A; Majdalani M; Kontogiorgis CA; Hadjipavlou-Litina D; Kefalas P
Bioorg Med Chem; 2009 Dec; 17(23):8073-85. PubMed ID: 19853459
[TBL] [Abstract][Full Text] [Related]
11. Development of multi-targetable chalcone derivatives bearing N-aryl piperazine moiety for the treatment of Alzheimer's disease.
Bajad NG; Singh RB; T A G; Gutti G; Kumar A; Krishnamurthy S; Singh SK
Bioorg Chem; 2024 Feb; 143():107082. PubMed ID: 38199142
[TBL] [Abstract][Full Text] [Related]
12. Syntheses and evaluation of novel isoliquiritigenin derivatives as potential dual inhibitors for amyloid-beta aggregation and 5-lipoxygenase.
Chen YP; Zhang ZY; Li YP; Li D; Huang SL; Gu LQ; Xu J; Huang ZS
Eur J Med Chem; 2013 Aug; 66():22-31. PubMed ID: 23786711
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological activity of multifunctional α,β-unsaturated carbonyl scaffolds for Alzheimer's disease.
Bag S; Ghosh S; Tulsan R; Sood A; Zhou W; Schifone C; Foster M; LeVine H; Török B; Török M
Bioorg Med Chem Lett; 2013 May; 23(9):2614-8. PubMed ID: 23540646
[TBL] [Abstract][Full Text] [Related]
14. Novel Potent and Selective Acetylcholinesterase Inhibitors as Potential Drugs for the Treatment of Alzheimer's Disease: Synthesis, Pharmacological Evaluation, and Molecular Modeling of Amino-Alkyl-Substituted Fluoro-Chalcones Derivatives.
Liu HR; Zhou C; Fan HQ; Tang JJ; Liu LB; Gao XH; Wang QA; Liu WK
Chem Biol Drug Des; 2015 Oct; 86(4):517-22. PubMed ID: 25588967
[TBL] [Abstract][Full Text] [Related]
15. Ethyl Acetohydroxamate Incorporated Chalcones: Unveiling a Novel Class of Chalcones for Multitarget Monoamine Oxidase-B Inhibitors Against Alzheimer's Disease.
Reeta ; Baek SC; Lee JP; Rangarajan TM; Ayushee ; Singh RP; Singh M; Mangiatordi GF; Nicolotti O; Kim H; Mathew B
CNS Neurol Disord Drug Targets; 2019; 18(8):643-654. PubMed ID: 31550216
[TBL] [Abstract][Full Text] [Related]
16. Rational design, synthesis and activities of hydroxylated chalcones as highly potent dual functional agents against Alzheimer's disease.
Liu Y; Han C; Dai R; Li B
Bioorg Chem; 2022 May; 122():105662. PubMed ID: 35276602
[TBL] [Abstract][Full Text] [Related]
17. Cholinesterases inhibition and molecular modeling studies of piperidyl-thienyl and 2-pyrazoline derivatives of chalcones.
Shah MS; Khan SU; Ejaz SA; Afridi S; Rizvi SUF; Najam-Ul-Haq M; Iqbal J
Biochem Biophys Res Commun; 2017 Jan; 482(4):615-624. PubMed ID: 27865835
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and evaluation of chalcone Mannich base derivatives as multifunctional agents for the potential treatment of Alzheimer's disease.
Zhang X; Song Q; Cao Z; Li Y; Tian C; Yang Z; Zhang H; Deng Y
Bioorg Chem; 2019 Jun; 87():395-408. PubMed ID: 30921741
[TBL] [Abstract][Full Text] [Related]
19. Exploiting the Chalcone Scaffold to Develop Multifunctional Agents for Alzheimer's Disease.
Rampa A; Bartolini M; Pruccoli L; Naldi M; Iriepa I; Moraleda I; Belluti F; Gobbi S; Tarozzi A; Bisi A
Molecules; 2018 Jul; 23(8):. PubMed ID: 30061534
[TBL] [Abstract][Full Text] [Related]
20. Amiridine-piperazine hybrids as cholinesterase inhibitors and potential multitarget agents for Alzheimer's disease treatment.
Makhaeva GF; Lushchekina SV; Kovaleva NV; Yu Astakhova T; Boltneva NP; Rudakova EV; Serebryakova OG; Proshin AN; Serkov IV; Trofimova TP; Tafeenko VA; Radchenko EV; Palyulin VA; Fisenko VP; Korábečný J; Soukup O; Richardson RJ
Bioorg Chem; 2021 Jul; 112():104974. PubMed ID: 34029971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
